Reliability of antiarrhythmic drug plasma concentration monitoring

Clinical Pharmacokinetics
F FollathE Schuetz

Abstract

Measurement of drug levels is becoming increasingly popular to optimise the dosage of various drugs. In the case of antiarrhythmic drugs, the narrow therapeutic margin of most of these agents and a direct relationship between their pharmacological effects and plasma concentrations would justify more widespread use of monitoring. Optimum plasma concentration ranges have been described for lignocaine (lidocaine), procainamide, quinidine and, more recently, also for disopyramide, mexiletine, tocainide and other new antiarrhythmics. A critical analysis of the original data shows, however, that therapeutic and toxic levels are not so well defined as often assumed: small numbers of patients, marked interindividual variability, sometimes inadequate documentation of arrhythmias and lack of standardised blood sampling characterise many of these studies. Uncertainty about the reliability of concentration-effect relationships also arises when active drug metabolites are identified or there are marked concentration-dependent changes of drug protein-binding. In addition, abolition of various types of arrhythmias might require different drug concentrations. Nevertheless, therapeutic monitoring can be of practical value in patients with life-...Continue Reading

Citations

Jan 1, 1995·Cancer Chemotherapy and Pharmacology·C A Jamis-DowJ M Collins
Apr 1, 1989·European Journal of Drug Metabolism and Pharmacokinetics·C KöppelF Martens
Sep 1, 2005·Pediatric Cardiology·V V DimasK E Ward
Jan 1, 1988·Journal of the American College of Cardiology·R LatiniA Volpi
Mar 1, 1991·British Journal of Clinical Pharmacology·K FattingerF Follath
Jul 10, 2002·Clinical Pharmacokinetics·Reza MehvarMajid Vakily
Nov 22, 2007·Clinical Pharmacokinetics·Ulrich Klotz
Nov 1, 1989·Medical Toxicology and Adverse Drug Experience·C P Denaro, N L Benowitz
Nov 1, 1984·British Journal of Clinical Pharmacology·J E Bredesen, P Kierulf
Dec 1, 1986·Journal of Veterinary Pharmacology and Therapeutics·M G PapichC A Davis
Jan 9, 2004·Infectious Disease Clinics of North America·John Turnidge
Sep 1, 1996·Clinical Pharmacology and Therapeutics·S LaganièreI McGilveray
Feb 1, 1987·Journal of Pharmacokinetics and Biopharmaceutics·M YasuharaC Kawai
Jan 1, 1989·British Journal of Pharmacology·Y HashimotoR Hori
Apr 1, 1986·Drug Intelligence & Clinical Pharmacy·B J Schrader, J L Bauman
Mar 1, 1996·The Annals of Pharmacotherapy·R LatiniU Guiducci
Dec 22, 2020·Journal of Cardiothoracic and Vascular Anesthesia·Daniel J KatzJordan E Goldhammer
Jul 13, 1984·Journal of Chromatography·O Grech-Bélanger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Related Papers

Clinical Pharmacokinetics
Gesche JürgensJens P Kampmann
Archives des maladies du coeur et des vaisseaux
B Flouvat
The American Journal of Cardiology
R A WinkleD C Harrison
© 2021 Meta ULC. All rights reserved